6533b7cffe1ef96bd125851d

RESEARCH PRODUCT

Additional file 2: of Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program

Markus MoehlerAnnett MadererAnne EhrlichFriedrich FoersterArno SchadTanja NickolayChristian RuckesArndt WeinmannVisvakanth SivanathanJens MarquardtPeter GalleMarcus WoernsThomas Thomaidis

subject

description

Table S2. Predefined disease limited toxicities. List with the disease limited toxicities associated with afatinib in this study. (DOC 36 kb)

https://dx.doi.org/10.6084/m9.figshare.7580969